Boston, US, and Rolle, Switzerland, September 7, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that the company is joining the European Liquid Biopsy Society (ELBS), a prestigious network consisting of partners from academia and industry with the common goal of making liquid biopsy tests part of the routine standard of care.

SOPHiA GENETICS offers a comprehensive suite of liquid biopsy applications that have helped progress oncology research and tumor mutation profiling. Liquid biopsy testing offers an alternative to solid tumor testing by isolating cell-free DNA (cfDNA) from blood plasma, which may uncover circulating tumor DNA (ctDNA). This non-invasive testing allows for cancer genomic profiling and disease monitoring. It reveals critical insights in many cases where genomic testing of tumor tissue may not be feasible due to insufficient tissue material, low quality of the obtained tissue, or the invasiveness of the procedure. 

The ELBS primarily focuses on liquid biopsy testing for cancer, which aligns with the work that SOPHiA GENETICS has done to increase access to this sophisticated testing. SOPHiA GENETICS decentralized MSK-ACCESS®, the highly validated ctDNA assay developed by Memorial Sloan Kettering Cancer Center (MSK), so customers in Europe and worldwide have access to a best-in-class liquid biopsy solution.

“ELBS facilitates scientific exchange, clinical studies, and networking between leading experts, and we are thrilled to have SOPHiA GENETICS bring their global expertise and insights to our dynamic network of partners as we advance the field of liquid biopsy,” said Dr. Klaus Pantel, Founder and Chairman of the ELBS.

“We are impressed by the expansive community that the ELBS has created and are looking forward to collaborating with the ELBS to move this groundbreaking field forward to further widespread adoption and reimbursement for liquid biopsy testing,” said Kevin Puylaert, Managing Director, EMEA, SOPHiA GENETICS.  “We believe that our participation will bring best-in-class technology and key learnings from our global community to complement and enhance the work of the ELBS moving forward.”

The ELBS network currently consists of more than 87 member institutions including academic institutions and university hospitals, as well as industry partners spread across biotech, device manufacturers, diagnostic companies, standard providers and pharmaceutical companies. Several members of the society, such as IUCT-Oncopole, work with SOPHiA GENETICS for liquid biopsy testing.

“We are pleased to welcome SOPHiA GENETICS to the European Liquid Biopsy Society. As the first laboratory in France and first European Liquid Biopsy member to adopt the MSK-ACCESS® powered with SOPHiA DDM™ application, we have experienced firsthand the technical expertise of the team at SOPHiA GENETICS combined with the analytical power of the SOPHiA DDM™ Platform to produce high-quality, meaningful insights for our teams. We are looking forward to continuing to further the field of liquid biopsy while serving our patients alongside the SOPHiA GENETICS team,” said a representative of the biology laboratory of medical oncology from IUCT-Oncopole in Toulouse.

###

About European Liquid Biopsy Society

The European Liquid Biopsy Society” Network was developed from the EU IMI “CANCER-ID” project (2015-2019) to further strengthen the field of Liquid Biopsy. The ELBS combines domestic and international orientation and promotes exchange between academic, industrial and clinical sectors as well as the health care system.

The network is further intended to promote the development of standardized guidelines and training in the field of “Liquid Biopsy” for physicians and researchers in related disciplines. The network, including third parties, also launches public relations campaigns on the subject of “Liquid Biopsy”, for example by sponsoring symposiums, presentations and press releases.

About SOPHiA GENETICS 

SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to unlock insights to deliver world-class care to patients across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions.  For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn. 

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence. 

SOPHiA GENETICS Forward-Looking Statements: This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Media Contact: 
Kelly Katapodis
[email protected]